Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Recent publications analyzing the relationship between local free energy and siRNA efficiency 4, 5 have demonstrated that mRNA target site secondary structure is of great importance for siRNA ...

The inaugural ADC Linker & Conjugation Summit has been specifically designed to drive innovations in linker and conjugation chemistries that result in stable ADCs, with low aggregation and ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis.

RNAi articles from across Nature Portfolio RNAi (RNA interference) is a biological process in which RNA molecules—microRNA (miRNA) and small interfering RNA (siRNA)—inhibit gene expression ...

A critical bottleneck for the use of metal–organic frameworks (MOFs) as drug delivery systems has been allowing them to reach their intracellular targets without being degraded in the acidic ...

The design of siRNAs is modular in nature: The chemical architecture, conjugated ligand, and/or delivery vehicle determines the siRNA’s tissue distribution and stability in a way that is largely ...